UPDATE 1-Amgen, Allergan say Avastin copycat succeeds in lung cancer study

September 23, 2015 2:43 PM

13 0

Sept 23 (Reuters) - Amgen Inc and Allergan Plc said a late-stage study showed their biosimilar candidate for a type of lung cancer was as effective as Roche AG's Avastin in preventing disease progression and improving survival.

Avastin is Roche's best-selling cancer drug, raking in about $6.5 billion in sales last year.

Also read: Coca-Cola Working to Turn War on Sugar Into a Profitable Venture

Read more

To category page